Orthocell Ltd (AU:OCC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orthocell Ltd is poised to broaden its international presence, targeting a $3 billion global market by expanding regulatory approvals for its Striate+ and Remplir medical devices in key markets, building on strong sales and a record $6.72 million revenue in FY24. Striate+ is gaining momentum in the dental industry while Remplir is making strides in nerve repair, with anticipated regulatory nods in Brazil, Singapore, and the US. Backed by a solid financial footing, the company is strategically advancing with seven new applications to capture a significant market share.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.